Here is my consolidated review.

---

## Summary

This paper proposes GANDALF, a generative data augmentation framework for cancer drug response prediction (DRP). The core idea is to generate "patient-like" genomic mutation samples from abundant cell line data, using a synthesis of denoising diffusion probabilistic models, variational autoencoders, transformers, and multi-task learning. GANDALF explicitly models the domain shift between cell lines and patients (different label spaces, different data distributions) — a gap prior methods either ignore or handle only in a shared latent space. The approach is evaluated on real patient datasets (TCGA, CBioPortal, Moores) against six state-of-the-art methods.

## Strengths

- **Novel approach to a genuine open problem.** The paper correctly identifies that prior DRP methods augment data only in a shared latent space, losing patient-specific characteristics. GANDALF'S proposal to generate labelled patient-like genomic samples *directly* from cell line data, while modeling the domain shift via separate prediction heads (AUDRC regression for cell lines, RECIST classification for patients) with CORAL alignment, is a well-motivated architectural contribution. This specific combination of DDPMs, VAEs, cross-attention, and multi-task learning for patient mutation augmentation is novel in the DRP literature.

- **Comprehensive ablation study confirms each component contributes.** The ablation (Table 2) systematically removes the MTL network, cross-attention, and the pretrained transformer encoder, showing the full model outperforms all ablated variants in both AUROC and AUPRC. This provides evidence that the architecture's complexity is warranted and that the components interact constructively.

- **Practical grounding in clinically realistic data.** The analysis is restricted to the 324 genes in the FoundationOne CDx clinical sequencing panel, ensuring the method is applicable to the genomic data actually available in clinical practice. The use of real patient cohorts (TCGA, CBioPortal, Moores) and multiple SOTA baselines (DruID, PREDICT-AI, drug2tme, PANCDR, CODE-AE, WISER) strengthens the practical relevance.

## Weaknesses

### Fatal
None.

### Major

- **Evaluation is limited to 5 out of 56 available drugs, undermining the headline claim.** The paper states that GANDALF "outperforms state-of-the-art DRP models" and demonstrates "an improvement of up to 10.96% over SOTA," yet the experimental comparison is restricted to exactly five drugs (Cisplatin, Paclitaxel, 5-Fluorouracil, Gemcitabine, Temozolomide) from a patient dataset that includes 56 drugs with documented responses. The stated selection criterion — "samples available in all 3 test folds" — is not quantified: no per-drug sample counts, class balance statistics, or sample size thresholds are reported. The 10.96% figure appears to be driven primarily by Temozolomide (AUROC 0.994 vs. 0.894 for the next best), while margins on other drugs are narrow (e.g., Paclitaxel 0.810 vs. 0.809). This is the single most significant weakness: the central empirical claim rests on a small and potentially unrepresentative subset of drugs, and the reader cannot assess whether the results generalize.

- **No statistical testing or variance reporting.** The paper reports only point estimates (AUROC, AUPRC) without standard deviations, confidence intervals, or any form of statistical test (e.g., paired tests across folds, bootstrap estimates). Given the small patient cohort (669 total: 541 TCGA + 44 Moores + 84 CBIO) and 3-fold cross-validation, the variance across folds is likely substantial. Without uncertainty quantification, it is impossible to determine whether the observed differences between GANDALF and competing methods are reliable or within the noise of the evaluation.

- **No experiment testing generalization to drugs not seen in the patient training data.** A stated advantage of the MTL network is that it can handle drugs outside the patient drug set ($d_p$) by leveraging cell line data. Yet no experiment validates this capability. The paper tests only drugs that appear in both patient and cell line training data. Without evidence that the augmentation pipeline improves prediction for drugs $\notin d_p$, a key practical claim of the framework remains unsubstantiated.

- **The core motivation — capturing "patient-specific characteristics" — is not empirically validated.** The paper argues that prior methods fail because they operate in a shared latent space that loses patient-specific factors, and that GANDALF addresses this by generating samples following $P(X_p)$. However, no analysis is provided showing that the generated samples actually differ from cell-line-derived samples in biologically meaningful ways, or that performance gains come from modeling patient-specific factors rather than from simple sample-size increase. The ablation removes cross-attention (which hurts performance), but this confounds sample quality with domain adherence. A direct comparison against training on an equal number of raw cell line samples (or a simple mix) would clarify the source of improvement.

- **Unaddressed risk of data leakage between pretraining and test cohorts.** The transformer encoder $T_e$ is pretrained on 71 NSCLC and 71 CRC samples from GENIE, while the downstream evaluation uses TCGA, CBioPortal, and Moores. Though GENIE is a separate consortium, no overlap check is performed or reported. If any patients appear in both GENIE and the test cohorts, the frozen representations learned during pretraining would be contaminated. This is a straightforward sanity check whose absence is a notable oversight.

### Minor

- **Pseudolabel selection thresholds $t_u$ and $t_l$ are not reported, nor is the number of retained confident samples $\mathbf{N}_s$.** The paper uses upper and lower thresholds to bin continuous pseudolabels into confident positive, confident negative, and abstained groups, but never states the threshold values or the procedure for setting them (beyond "validation set correlation"). Without this, the reader cannot assess how much the augmentation actually expands the training set or whether the threshold choice drives the observed performance. The ablation shows the full model is best, but this could reflect threshold tuning as much as architectural choices.

- **Comparison with WISER and CODE-AE is incomplete and unexplained.** According to Table 1, these methods have missing entries for multiple drugs (e.g., CODE-AE no data for several drugs; WISER evaluated on only 2 of 5). The paper does not explain why these baselines could not be evaluated on all five drugs. If the reason is insufficient drug-specific samples, that limitation equally applies to GANDALF's drug-specific tuning, making the comparison asymmetric. This weakens the claim that GANDALF "outperforms" these specific baselines.

- **No per-fold results reported.** The paper uses 3-fold cross-validation on a small patient cohort, but reports only aggregated metrics. Fold-wise AUROC/AUPRC should be provided to help readers assess stability.

### Trivial

- The naive Gaussian perturbation baseline ("W perturbation") is described only in prose rather than included in Table 2 alongside other methods, making side-by-side comparison harder than necessary.
- Per-drug sample counts in the test folds for each of the five evaluated drugs are not provided, which would aid interpretability.

## Nice-to-Haves

- An experiment explicitly testing whether generated samples capture patient-specific characteristics: e.g., train a domain classifier to distinguish generated samples from cell line samples and measure domain confusion; compare drug-response distributions of generated vs. real patient profiles.
- An experiment holding out one or two drugs from patient training data entirely, using the MTL network and cell line data to generate pseudolabels, and comparing against a model trained on cell line data alone.
- A sensitivity analysis of the pseudolabel thresholds ($t_u$, $t_l$) showing how performance varies across reasonable ranges.
- Reporting of computational cost (training time, GPU hours) given the large number of sub-modules.
- Reporting fold-wise results for all experiments.

## Removed Points

- **Criticism about typographical artifacts in Algorithm 1 (line garbling).** These are PDF extraction artifacts, not author errors. The underlying algorithmic logic is described in the main text (Sections 3.2.1–3.2.5).
- **Criticism about the code link needing to be "permanent."** The paper provides an anonymous code link, which is standard for double-blind review; the existence of the code is not in question.
- **Criticism that the paper's "first to tackle" claim may not hold because generative models appear in other bioinformatics contexts (single-cell data).** The paper's claim is specifically about *patient mutation data augmentation for cancer DRP*, which is distinct from transcriptomic augmentation or single-cell contexts. This is a framing disagreement, not a demonstrable error.
- **Criticism about missing appendix/proofs.** These are parser-stripped sections that exist in the original submission.

## Novel Insights

None beyond the paper's own contributions. The reviews surface known tensions in this line of work: generative augmentation for sparse clinical data is a promising direction, but evaluating it convincingly requires either substantially more drugs or substantially more patients per drug than what current public cohorts provide. The 5-drug ceiling is not unique to this paper — it reflects a systemic data limitation in the field — but the paper does not adequately grapple with how this limits the strength of its claims.

## Suggestions

1. **Expand the drug evaluation.** Either evaluate on all drugs with any test samples (reporting sample counts per drug and flagging drugs with too few samples for reliable estimation) or clearly state the sample-size floor and justify it. Include confidence intervals or bootstrap estimates.
2. **Add statistical rigor.** Report standard deviations or confidence intervals for all metrics, ideally via bootstrap or per-fold reporting.
3. **Run a held-out-drug experiment.** Hold out patient data for 1–2 drugs, generate pseudolabels via the MTL network, and compare against a cell-line-only classifier. This directly tests a claimed advantage of the framework.
4. **Validate the patient-specificity claim.** Compare generated samples against both real patient profiles and cell line profiles using a domain classifier or distributional distance metric. Show that the improvement over baselines is not merely an artifact of increased sample size.
5. **Report overlap check** between GENIE pretraining samples and all test cohorts.
6. **Report pseudolabel thresholds and retained sample counts.** Ideally include a sensitivity analysis showing robustness to threshold choice.

## Score and Decision

The paper tackles a genuine problem with a well-motivated, novel architecture. The ablation study convincingly shows that the components work together. However, the empirical evaluation rests on only 5 of 56 available drugs, lacks any statistical uncertainty quantification, and fails to validate the paper's central conceptual claim (that patient-specific characteristics are being captured rather than just sample size being increased). The missing overlap check and unaddressed potential for data leakage add further uncertainty. These are not minor presentation issues — they are gaps in the evidence required to support the paper's core claims. While the architectural ideas have real potential and could form the basis of a significantly stronger submission, in its current form the evidence is insufficient.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>